5 completed, 1 active not recruiting, 1 terminated. 6 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Active not recruiting 1, Terminated 1 |
| Phase 1 | 4 | Completed 4 |
Follow BMS-813160: new trials by email Literature Review of BMS-813160 trials Research Report on BMS-813160
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) Nivolumab, BMS-813160, BMS-986253 - Non-small Cell Lung Cancer, Hepatocellular Carcinoma | Phase 2 | Active not recruiting | Icahn School of Medicine at Mount Sinai | 48 | 2020-03-05 | 2026-09-25 |
| Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. Stereotactic Body Radiation (SBRT), Nivolumab, CCR2/CCR5 dual antagonist - Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 22 | 2019-12-12 | 2026-05-11 |
| BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) BMS-813160, Nivolumab, Gemcitabine - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 40 | 2018-08-31 | 2025-07-29 |
| A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors BMS-813160, Nivolumab, Nab-paclitaxel - Colorectal Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 332 | 2017-08-08 | 2025-10-09 |
| A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma Nivolumab, Ipilimumab, Relatlimab - Advanced Cancer | Phase 2 | Completed | Bristol-Myers Squibb | 182 | 2017-02-02 | 2022-12-19 |
| Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease BMS-813160, Placebo matching with BMS-813160 - Diabetic Kidney Disease | Phase 2 | Terminated | Bristol-Myers Squibb | 319 | 2013-03-18 | 2019-07-30 |
| Single Ascending Dose (BMS-813160) Study BMS-813160, [14C] BMS-813160, Placebo - Accelerated Intimal Hyperplasia | Phase 1 | Completed | Bristol-Myers Squibb | 70 | 2010-02-01 | 2011-02-11 |
Pancreatic Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Diabetic Nephropathies (1)
Bristol-Myers Squibb (4) · Icahn School of Medicine at Mount Sinai (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Washington University School of Medicine (1)
United States (7) · Canada (3) · Australia (2) · Austria (1) · Belgium (1) · Denmark (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Spain (1)
Amol Narang, MD (1) · Kian-Huat Lim, M.D., Ph.D. (1) · Thomas Marron, MD PhD (1)
2016 (1), 2017 (1), P50CA196510 (1)